リリースコンテナ第3倉庫

“We are pleased to have SUMMUS Software actively promote the many benefits associated with SAM implementation. In addition to reducing risk that comes from unlicensed software such as malware and fines, SAM adopting organizations will find increased IT efficiencies”

CSS(O) is the IT industry’s first enterprise-level certification that affirms an organization’s SAM processes are aligned to the ISO 19770-1 SAM standard and is compliant with its software license agreements. Developed by BSA in collaboration with leading independent auditors KPMG and Deloitte Touche, CSS(O) is the only industry certification based on ISO SAM. By becoming CSS(O), companies reduce their exposure to legal, financial and security risks caused by software piracy, software license non-compliance, and greatly benefit from streamlined IT operational efficiencies.

SUMMUS is the industry’s first and only customer-proven IT management solution provider to have incorporated all of the key CSS(O) SAM process requirements in its IT asset management (ITAM) product, Summus Asset Management. Built on the Summit Platform, Summus Asset Management is the ITAM component of the Summus IT Management Suite, and provides the following CSS(O)-compliant capabilities: white-list/black-list software inventory, centralized uninstall of black-listed software, software usage metering, end-user usage variance reporting and alerts, automated linkage of software installations and provisioning requests to compliant license inventory.

Wai Wong, President and CEO of SUMMUS Software, said, “Organizations worldwide are regularly faced with the prospects of license compliance audit requests from software publishers with the associated potential risks for substantial financial, legal and security liabilities. By offering the industry’s first ISO SAM and CSS(O)-enabling ITAM solution, SUMMUS is helping customers to effectively manage costs and minimize exposure to potential risks from their software assets.”

“We are pleased to have SUMMUS Software actively promote the many benefits associated with SAM implementation. In addition to reducing risk that comes from unlicensed software such as malware and fines, SAM adopting organizations will find increased IT efficiencies,” said Peter Beruk, Senior Director, Compliance Marketing for the Business Software Alliance.

Founded in 1988, the Business Software Alliance is a leading international IT industry group whose mission is to promote conditions in which the information technology industry can thrive and contribute to the prosperity, security, and quality of life of all people. For more information, visit www.bsa.org.

About SUMMUS Software

SUMMUS Software is a cloud-based provider of integrated and comprehensive IT service management, asset management and availability management solutions. Enterprises worldwide are using SUMMUS Software’s comprehensive cloud-based Summus IT Management Suite solutions to cost-effectively and flexibly assure IT operations for on-premise and cloud-based infrastructure. For more information, visit http://summussoftware.com, and follow us @summussoftware on Twitter.

“At its core, the Green Portfolio Program has always been about partnership, collaboration and creating sustainable value”

“We launched the Green Portfolio Program with Environmental Defense Fund because we believed environmental innovation would pay off for our portfolio companies and we are pleased to see the program making such progress,” said George Roberts, Co-Founder and Co-Chief Executive Officer of KKR. “The expanding global reach of the program speaks volumes about the common understanding that good business and improving the environment are often inextricably linked.”

Reporting for the first time are: A.T.U., First Data, Oriental Brewery, Pets at Home, Tarkett and WILD Flavors. The U.S.-based companies already participating in the program are: Accellent, Biomet, Dollar General, HCA, Sealy, SunGard, and US Foods. Due to the fact that Primedia is no longer a KKR portfolio company, it is not reporting into the program. A.T.U., based in Germany, is a new participant in the program.

Three other companies joined the Green Portfolio Program in 2010 and will report results in 2012: Bis Industries Limited, located in Australia; Van Gansewinkel Groep, located in The Netherlands; and Visant Corporation, located in New York.

“At its core, the Green Portfolio Program has always been about partnership, collaboration and creating sustainable value,” said Ken Mehlman, Head of Global Public Affairs and a Member of KKR. “While there is always more to do, these results reflect continued momentum that is driving a positive impact on the environment and across our private equity portfolio.”

Launched in May 2008 as a partnership between KKR and Environmental Defense Fund, the KKR Green Portfolio Program offers a set of analytic tools and metrics to help companies measure and improve environmental performance, including greenhouse gas emissions, waste generation, and use of water, forest resources and priority chemicals. These tools help managers cost effectively improve efficiency and reduce waste, which leads to cost savings.

“Today’s institutional investors want their dollars to create both financial returns and environmental and social value,” said Gwen Ruta, Vice President of Environmental Defense Fund. “KKR’s Green Portfolio program is a great model for investors who want to see rigorous and transparent environmental results.”

The Green Portfolio Program is part of a broader effort at KKR to create sustainable long-term value by addressing environmental, social and governance (“ESG”) issues in its private equity investments. As part of this effort, KKR has added talent to its team of individuals focused on ESG issues. In late 2011, KKR hired an ESG and Stakeholder Engagement Manager, resulting in two full-time employees focused entirely on these issues.

In 2009 KKR became a signatory of the globally recognized voluntary framework of the United Nations-backed Principles for Responsible Investment. KKR also has built a network of external partners, including, Business for Social Responsibility, Center for American Progress, and CSR Europe. These organizations regularly help KKR and its portfolio companies understand and address various ESG issues. More information on all of these efforts is included in KKR’s first sustainability report, available at http://www.kkrannualreport.com. Details on the Green Portfolio Program results, including what the portfolio companies have done to achieve them, can be found at www.green.kkr.com.

About KKR

Founded in 1976 by Henry Kravis and George Roberts, KKR is a leading global investment firm with $58.7 billion in assets under management as of September 30, 2011. With offices around the world, KKR manages assets through a variety of investment funds and accounts covering multiple asset classes. KKR seeks to create value by bringing operational expertise to its portfolio companies and through active oversight and monitoring of its investments. KKR complements its investment expertise and strengthens interactions with investors through its client relationships and capital markets platform. KKR is publicly traded on the New York Stock Exchange (NYSE: KKR). For additional information, please visit KKR's website at www.kkr.com.

“First To File’s priority is always to protect its clients and their data, and we are dedicated to performing at the highest level in that regard”

SSAE 16 is an improvement to the SAS70. Companies who complete an annual SOC 1 (SSAE 16) examination are able to demonstrate a substantially higher level of assurance and operational visibility than those companies who do not.

The completion of the SOC 1 (SSAE 16) Type II examination typifies First To File’s continued commitment to create and maintain the most stringent controls needed to provide the highest quality and security of services to their customers. The Service Auditors’ Report demonstrates that First To File’s control activities were effectively designed and in operation throughout the reporting period.

“First To File’s priority is always to protect its clients and their data, and we are dedicated to performing at the highest level in that regard,” remarked James Bergeron, CEO of First To File. “SSAE 16 certification is the gold standard in customer protection and transparency and we are proud to have achieved this distinction. Our clients will benefit from our continued adherence to the SSAE guidelines, and we are committed to upholding these principles for years to come.”

The Service Auditors’ Report includes a detailed description of First To File’s controls and an independent assessment of whether the controls are placed in operation, suitably designed, and operating effectively. To receive a copy of the Service Auditors’ Report, or for any further questions, please contact Kurt Wedel at kwedel@firsttofile.com.

About First To File

First To File’s Electronic File Room (EFR) is the world’s leading Web-based patent prosecution support and document management service. The secure SaaS solution eliminates costly paper storage and management, providing automated, all-digital filing and prosecution. EFR provides organizations of all sizes with enhanced collaboration, improved quality, reduced risk, and total visibility of all patent-related assets, while restricting access to sensitive material consistent with the preservation of client confidentiality and attorney/client privilege. First To File is a privately held company that is headquartered in San Mateo, Calif. For more information, visit the company website www.firsttofile.com or follow us on Twitter @FirstToFile

The global financial crisis showed the crippling effect poor liquidity risk management can have on markets and on firms.

In its wake, market practitioners and regulators alike recognise the necessity of effective management of liquidity and assessment of risks. Yet liquidity remains fuzzy even at a conceptual level, and liquidity risk management an emerging discipline.

Liquidity Modelling by Robert Fiedler is a guide on how to model and manage liquidity risk for financial market practitioners.

The author's practical approach equips the reader with the tools to understand the components of liquidity risk, how they interact and, as a result, to build a quantitative model to display, measure and limit risk.

Liquidity risk is hard to understand. It needs to be broken down into its components and drivers in order to manage and model it successfully.

The market turmoil that began in mid-2007 re-emphasised the importance of liquidity to the functioning of financial markets and the banking sector. In advance of the turmoil, asset markets were buoyant and funding was readily available at low cost. The reversal in market conditions illustrated how quickly liquidity can evaporate and that illiquidity can last for an extended period of time. Financial regulators across the globe are urging institutions to address this dimension of financial risk more comprehensively.

In this comprehensive guide to modelling liquidity risk, Robert Fiedler provides a coherent model which allows the reader to understand the components of illiquidity risk and how they interact and as a result enable you to build a quantitative model to display, measure and limit risk.

Liquidity Modelling is required reading for financial market practitioners who are dealing with liquidity risk and who want to understand it.

Key Topics Covered:

1 Introduction

2 Setting the Scene: Why Liquidity Is Important in a Bank

3 What Is Liquidity Risk?

4 Illiquidity Risk: The Foundations of Modelling

5 Capturing Uncertainties

6 A Template for an Illiquidity Risk Solution

7 The Counterbalancing Capacity

8 Intra-Day Liquidity Risk

9 Liquidity Transfer Pricing and Limits

10 The Basel III Banking Regulation

For more information visit http://www.researchandmarkets.com/research/93b01c/liquidity_modellin

“We are pleased to help Dumbarton House reduce its carbon footprint”

“After researching ways to be better stewards of the environment, we found that the purchase of 100% WGES CleanSteps^® Carbon Offsets matched to our natural gas usage was a logical next step,” said Karen L. Daly, Executive Director of Dumbarton House. “This purchase reflects Dumbarton House’s commitment to supporting Sustainable DC efforts to make the District the greenest, healthiest, most livable city in the country.”

Since the September 2010 launch of WGES CleanSteps^® Carbon Offsets, customer purchases are equivalent to eliminating nearly 19,000 metric tons of carbon dioxide from the air or taking 3,900 cars off the road for a full year. These purchases also prompted more than $100,000 in funding from WGES to the Chesapeake Bay Foundation’s Carbon Reduction Fund, which provides grants to farmers to aid in nutrient management efforts and support for local tree plantings.

"We are pleased to help Dumbarton House reduce its carbon footprint," said Harry Warren, president of Washington Gas Energy Services. "We commend the museum for their environmental leadership by demonstrating that simple steps can have a big impact on improving our local environment.”

About Washington Gas Energy Services

Washington Gas Energy Services, Inc. is one of the largest competitive providers of electricity and natural gas in the mid-Atlantic region and supplies more than 350,000 customers in Maryland, Delaware, the District of Columbia, Pennsylvania and Virginia. Headquartered in Herndon, Va., Washington Gas Energy Services is an affiliate of Washington Gas and a subsidiary of WGL Holdings, Inc. (NYSE:WGL). www.wges.com.

About Dumbarton House

The mission of the Dumbarton House museum, a Federal Period historic house, ca. 1800, is to preserve the historic structure and its collections and to educate the public about life in Washington, D.C., during the early years of the Republic. Emphasis is placed on Joseph Nourse, first Register of the Treasury, and his family, and their occupation of the property from 1804 through 1813. www.dumbartonhouse.org

The milestone agreement with Sony Pictures Television is the latest in a line of exclusive content deals announced by Amazon’s LOVEFiLM in the UK in recent months, including deals with Warner Bros., Entertainment One, STUDIOCANAL, Disney, Momentum and Lionsgate.

LOVEFiLM members will be able to exclusively stream Sony Pictures titles, including the Academy Award-winning The Social Network, action-thriller Salt, starring Angelina Jolie, and sci-fi action blockbuster 2012 via LOVEFiLM Instant at no extra cost and as part of their existing subscription.

The deal will also further bolster LOVEFiLM’s extensive range of kids TV titles with modern cult, animation favorites like Transformers, Spectacular Spider-Man and The Karate Kid – adding a raft of series to existing LOVEFiLM catalog titles like Pingu, Wallace & Gromit and Fireman Sam.

In addition, LOVEFiLM members will have exclusive streaming access during this pay window to a host of future releases from Sony Pictures, including the No. 1 box office hit Arthur Christmas.

The deal will see Sony Pictures’ recent and forthcoming releases, catalog titles and TV series added to the LOVEFiLM Instant service – available on the PC or via Sony PlayStation®3, Microsoft Xbox 360, Apple iPad®, and a growing number of Internet-connected TV sets and Blu-ray players.

Amazon’s LOVEFiLM will continue to rent Sony Pictures titles on DVD and Blu-ray via its LOVEFiLM By Post service.

Simon Calver, Chief Executive of Amazon’s LOVEFiLM, said:

“Our latest major content agreement means we’ll be able to exclusively offer our members world-class content from Sony Pictures. The number of recent high-profile deals we have secured means we are able to keep expanding the service, offering our members high-quality films and TV and the ability to watch as much as they want for one low monthly price.”

For further information, please contact the LOVEFiLM press office at Mischief on 020 3128 6600 or lovefilm@mischiefpr.com.

Links to editors

Amazon’s LOVEFiLM Expands UK Content With Sony Pictures TV Deal:

http://corporate.blog.lovefilm.com/

LOVEFiLM Instant:

http://www.lovefilm.com/browse/film/watch-online/

LOVEFiLM:

http://www.lovefilm.com

http://www.facebook.com/LOVEFILM

http://twitter.com/LOVEFiLM

About LOVEFiLM

• LOVEFiLM is an Amazon company and is the leading European film subscription service with more than 1.8 million members in the UK, Germany, Sweden, Denmark, and Norway
• In February 2011, LOVEFiLM was acquired by Amazon EU SARL
• LOVEFiLM members can enjoy the benefits of DVDs delivered straight to their door with LOVEFiLM By Post and streaming films online via LOVEFiLM Instant
• LOVEFiLM Instant is available on over 175 Internet-enabled devices including PCs, PlayStation®3, iPad®, Xbox 360, plus a growing number of Blu-Ray players and Internet-connected TVs including Sony, Samsung and Cello
• LOVEFiLM is available for as little as £4.99 a month – with no late fees
• Titles are also available to everyone on a pay-per-view basis via LOVEFiLM Box Office
• Members can choose from a selection of over 70,000 titles available across Blu-ray, DVDs, video games and instant streaming
• LOVEFiLM offers a range of video games rental options in the UK market to support gaming across Xbox 360, Xbox, PlayStation®3, PlayStation®2, Wii and DS
• LOVEFiLM members have generated over 80 million film ratings and written more than 843,000 reviews
• For additional information including a breakdown of packages, visit www.lovefilm.com

About Amazon.com

Amazon.com, Inc. (NASDAQ: AMZN), a Fortune 500 company based in Seattle, opened on the World Wide Web in July 1995 and today offers Earth’s Biggest Selection. Amazon.com, Inc. seeks to be Earth’s most customer-centric company, where customers can find and discover anything they might want to buy online, and endeavors to offer its customers the lowest possible prices. Amazon.com and other sellers offer millions of unique new, refurbished and used items in categories such as Books; Movies, Music & Games; Digital Downloads; Electronics & Computers; Home & Garden; Toys, Kids & Baby; Grocery; Apparel, Shoes & Jewelry; Health & Beauty; Sports & Outdoors; and Tools, Auto & Industrial. Amazon Web Services provides Amazon’s developer customers with access to in-the-cloud infrastructure services based on Amazon’s own back-end technology platform, which developers can use to enable virtually any type of business. The new latest generation Kindle is the lightest, most compact Kindle ever and features the same 6-inch, most advanced electronic ink display that reads like real paper even in bright sunlight. Kindle Touch is a new addition to the Kindle family with an easy-to-use touch screen that makes it easier than ever to turn pages, search, shop, and take notes – still with all the benefits of the most advanced electronic ink display. Kindle Touch 3G is the top of the line e-reader and offers the same new design and features of Kindle Touch, with the unparalleled added convenience of free 3G. Kindle Fire is the Kindle for movies, TV shows, music, books, magazines, apps, games and web browsing with all the content, free storage in the Amazon Cloud, Whispersync, Amazon Silk (Amazon’s new revolutionary cloud-accelerated web browser), vibrant color touch screen, and powerful dual-core processor.

Amazon and its affiliates operate websites, including www.amazon.com, www.amazon.co.uk, www.amazon.de, www.amazon.co.jp, www.amazon.fr, www.amazon.ca, www.amazon.cn, www.amazon.it, and www.amazon.es. As used herein, “Amazon.com,” “we,” “our” and similar terms include Amazon.com, Inc., and its subsidiaries, unless the context indicates otherwise.

Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Actual results may differ significantly from management's expectations. These forward-looking statements involve risks and uncertainties that include, among others, risks related to competition, management of growth, new products, services and technologies, potential fluctuations in operating results, international expansion, outcomes of legal proceedings and claims, fulfillment center optimization, seasonality, commercial agreements, acquisitions and strategic transactions, foreign exchange rates, system interruption, inventory, government regulation and taxation, payments and fraud. More information about factors that potentially could affect Amazon.com's financial results is included in Amazon.com's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent filings.

Millwater will remain with Willis Group in 2012 and will provide consulting support in 2013 to ensure a smooth transition. His responsibilities at the group and business unit level will be assumed in January by senior Willis executives Steve Hearn and Tim Wright.

Joe Plumeri, Chairman and CEO of Willis Group, hailed Millwater’s achievements recorded in over a quarter century of service to the company. “My partnership, and friendship, with Grahame began upon my arrival to Willis in 2000 and continues to this day. I join everyone at Willis in offering Grahame, and his family, my deep gratitude for his enormous contributions to our success over the past 26 years. We wish him all the very best wherever his future career may take him,” Plumeri said.

Millwater added: “After spending my entire professional career since leaving university with one company, I have been privileged to work with an extraordinary team of people from around the world and am retiring from Willis with many friends. I’m grateful to Joe for the many leadership roles I’ve enjoyed over the past decade and look forward to spending some time with my family and considering new opportunities.”

Steve Hearn, who was appointed CEO of Willis Re early this year after serving as head of Willis’ London Market Wholesale Businesses will, as of January 1, serve as Chairman and CEO of Willis Global in addition to his duties as CEO of Willis Re. Willis Global includes Willis Re, Willis Global Specialties, Willis Faber & Dumas, Willis Global Solutions and Willis Global Placement. Hearn will also serve as member of the Willis Group Operating Committee.

In the retail business, Tim Wright, who was appointed CEO of Willis International in October 2011 after joining the company as Group COO in 2008 will, as of January 1, also oversee Willis UK & Ireland, which is headed by Dan Wilkinson.

Willis Group Holdings plc is a leading global insurance broker. Through its subsidiaries, Willis develops and delivers professional insurance, reinsurance, risk management, financial and human resource consulting and actuarial services to corporations, public entities and institutions around the world. Willis has more than 400 offices in nearly 120 countries, with a global team of approximately 17,000 employees serving clients in virtually every part of the world. Additional information on Willis may be found at www.willis.com.

“2011 has been an important year for understanding the role of platelet reactivity testing in clinical practice”

In 2011, four new published Guidelines included recommendations about platelet reactivity testing for patients on antiplatelet therapy: ACCF/AHA about UA/NSTEMI patients¹, ACCF/AHA/SCAI about PCI patients², ESC about NSTE-ACS patients³, and STS/SCA about surgical patients⁴. Included in the guidelines are recommendations that address treatment strategies based on platelet reactivity.

Throughout the year, new clinical data was published underscoring the value of platelet reactivity testing, including a pharmacodynamic analysis from the GRAVITAS trial indicating that low platelet reactivity was significantly associated with a lower risk of adverse cardiovascular events⁵. Also published was a 3,000+ patient meta-analysis demonstrating that patients with high platelet reactivity exhibited more than twice the rate of death, heart attack and stent thrombosis⁶.

Accumetrics strengthened its position as a global diagnostic leader by achieving CE marking outside the US for its VerifyNow P2Y12 Test for prognostic use in identifying patients with high residual platelet reactivity on antiplatelet therapy who are at greater risk for future cardiovascular events.

"2011 has been an important year for understanding the role of platelet reactivity testing in clinical practice,” said Matthew J. Price, MD, of the Scripps Translational Science Institute and Scripps Clinic in La Jolla, CA. "Reported findings in multiple abstract presentations and published studies, consisting in total of more than 20,000 patients, continue to confirm the strong association between high platelet reactivity and the risk of recurrent cardiovascular events, including stent thrombosis, after PCI. The 2011 guidelines now include the consideration for platelet reactivity testing in managing patients with ACS and/or PCI. Upon this foundation, we are now entering the era of generic clopidogrel, which will markedly change the cost dynamics of antiplatelet therapy. All of this emphasizes the emerging impact of platelet reactivity testing to help the physician provide the best care of our higher risk PCI patients."

Accumetrics experienced solid growth in 2011 across all of its sales channels. The Company expects to conclude the year with roughly $21 million in annual revenue, and an expanded installed base. The VerifyNow System is used clinically by physicians in over 700 facilities in the United States and over 70 countries worldwide where antiplatelet medications are prescribed to reduce the occurrence of future thrombotic events such as heart attack and stroke.

“With the advent of generic clopidogrel in the US in 2012, healthcare providers and payers alike will be seeking the most cost effective and clinically appropriate antiplatelet therapy for individual patients,” said Timothy I. Still, President and CEO of Accumetrics. “Accumetrics is pleased to offer an innovative and cost-effective point-of-care solution that addresses the need for clinicians to better understand the effect of their treatment decisions, ultimately benefitting public health.”

About Accumetrics

Accumetrics is committed to advancing medical understanding of platelet function and enhancing quality of care for patients receiving antiplatelet therapies by providing industry-leading and widely accessible diagnostic tests for rapid platelet function assessment.

Accumetrics’ VerifyNow System is the first rapid and easy-to-use platform to help physicians determine an individual’s response to multiple antiplatelet agents. Addressing every major antiplatelet drug, including FDA-cleared products for aspirin, P2Y12 inhibitors (e.g. prasugrel (Effient^®) and clopidogrel (Plavix^®)), and GP IIb/IIIa inhibitors (e.g. ReoPro^® and Integrilin^®), the VerifyNow System provides valuable information to help physicians make informed treatment decisions. The VerifyNow P2Y12 Test is a whole blood assay used in the laboratory or point of care setting to measure the level of platelet P2Y12 receptor blockade. Additionally, it is indicated outside the US for evaluating the risk for recurrent events in cardiovascular patients.

For more information about the Company and its products, visit www.accumetrics.com.

The Accumetrics logo and VerifyNow are registered trademarks of Accumetrics, Inc. ReoPro is a registered trademark of Centocor, Inc. Integrilin is a registered trademark of Millennium Pharmaceuticals. Plavix is a registered trademark of Bristol Myers Squibb/Sanofi Pharmaceuticals Partnership. Effient is a registered trademark of Eli Lilly and Company.

¹ Wright RS, et al. J Am Coll Cardiol 2011; 57:1920-1959
² Levine, GN. et al. J. Am. Coll. Cardiol. Published online Nov 7, 2011; doi:10.1016/j.jacc.2011.08.007
³ Hamm, CW. et al. Eur Heart J (2011) first published online August 26, 2011 doi:10.1093/eurheartj/ehr236
⁴ Ferraris, VA. et al. Ann Thorac Surg. 2011 Mar;91(3):944-82
⁵ Price, MJ. et al Circulation. 2011;124:1132-1137
⁶ Brar, S et al. J Am Coll Cardiol 2011;58:1945–54

“In just three and a half years, Impax’s brand research and development team has successfully advanced IPX066 from an Investigational New Drug (IND) through multiple clinical studies of efficacy and safety, culminating in our NDA submission”

“In just three and a half years, Impax’s brand research and development team has successfully advanced IPX066 from an Investigational New Drug (IND) through multiple clinical studies of efficacy and safety, culminating in our NDA submission,” said Michael Nestor, president of Impax Pharmaceuticals. “This event demonstrates our strong internal capability to develop neurology products to fulfill unmet clinical needs of the PD community. IPX066 represents a significant commercial opportunity for Impax in the U.S., which if approved we plan to commercialize with our specialty neurology sales team.”

IPX066 has undergone extensive clinical development, including multiple studies in early and advanced PD in the U.S. and in Europe. As agreed with the FDA, the NDA is being submitted as a 505(b)(2) application and includes data from three controlled Phase III studies and two open label extensions of IPX066 in early and advanced PD. In these studies, IPX066 has been studied in about 900 PD subjects. Impax held an end of Phase III meeting with the U.S. FDA in the third quarter of 2011 and is submitting its NDA consistent with the guidance it received.

“We are proud to achieve this important milestone in our development of the brand pharmaceutical business,” said Larry Hsu, Ph.D., president and CEO of Impax Laboratories, Inc. “This represents an important part of our strategy to diversify our business model to branded products, with the objective of improving long-term shareholder value.”

About IPX066

IPX066 is an investigational extended release capsule formulation of CD-LD which is intended to maintain consistent plasma concentration of levodopa for a longer duration versus immediate release levodopa, which may have an impact on fluctuations in clinical response. It is not approved or licensed anywhere in the world.

Results from the pivotal phase III studies of IPX066, APEX-PD (early PD), ADVANCE-PD (advanced PD) and ASCEND-PD (advanced PD) have previously been announced. Results of the ASCEND-PD study and other IPX066 data are planned for submission to the American Academy of Neurology and International Congress of Parkinson’s Disease and Movement Disorders Conference in April and June 2012, respectively.

About the Impax GSK collaboration

Impax Pharmaceuticals and GSK announced an agreement for the development and commercialization of IPX066 in December 2010. Under the terms of the agreement, GSK received an exclusive license to register and commercialize IPX066 throughout the world except in the U.S. and Taiwan.

About Parkinson’s Disease

Parkinson’s disease is a chronic neurodegenerative movement disorder affecting over three million people in the US, Europe, and Japan.

About Impax Laboratories, Inc.

Impax Laboratories, Inc. is a technology-based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of branded products. Impax markets its generic products through its Global Pharmaceuticals division and markets its branded products through the Impax Pharmaceuticals division. Additionally, where strategically appropriate, Impax has developed marketing partnerships to fully leverage its technology platform. Impax is headquartered in Hayward, California, with a full range of capabilities located in its Hayward, Philadelphia and Taiwan facilities. For more information, please visit the Company's Web site at: www.impaxlabs.com.

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:

To the extent any statements made in this news release contain information that is not historical, these statements are forward-looking in nature and express the beliefs and expectations of management. Such statements are based on current expectations and involve a number of known and unknown risks and uncertainties that could cause the Company’s future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to, the effect of current economic conditions on the Company’s industry, business, financial position and results of operations, the ability to maintain an effective system of internal control over financial reporting, fluctuations in revenues and operating income, the ability to successfully develop and commercialize pharmaceutical products, reductions or loss of business with any significant customer or a reduction in sales of any significant product, the impact of competition, the ability to sustain profitability and positive cash flows, any delays or unanticipated expenses in connection with the operation of the Taiwan facility, the effect of foreign economic, political, legal and other risks on operations abroad, the uncertainty of patent litigation, consumer acceptance and demand for new pharmaceutical products, the difficulty of predicting Food and Drug Administration filings and approvals, the inexperience of the Company in conducting clinical trials and submitting new drug applications, the ability to successfully conduct clinical trials, reliance on alliance and collaboration agreements, the availability of raw materials, the ability to comply with legal and regulatory requirements governing the pharmaceutical and healthcare industries, the regulatory environment, the ability to protect the Company’s intellectual property, exposure to product liability claims and other risks described in the Company’s periodic reports filed with the Securities and Exchange Commission. Forward-looking statements speak only as to the date on which they are made, and Impax undertakes no obligation to update publicly or revise any forward-looking statement, regardless of whether new information becomes available, future developments occur or otherwise.

“Conference Plus is a well-run operation that has contributed significantly to Westell over many years”

“Conference Plus is a well-run operation that has contributed significantly to Westell over many years,” said Rick Gilbert, Westell’s chairman and chief executive officer. “While we are proud of its accomplishments, we have concluded that it should be even more successful as a part of a larger conferencing business. We think the combination of Conference Plus with Arkadin is the right opportunity, benefiting customers and both organizations. The sale is also good for Westell and will allow us to focus on growing our core telecommunications networking equipment business.”

About Westell

Westell Technologies, Inc., headquartered in Aurora, Illinois, is a holding company for Westell, Inc. and Conference Plus, Inc. Westell, Inc. designs, distributes, markets and services a broad range of broadband customer-premises equipment, digital transmission, remote monitoring, power distribution and demarcation products used by telephone companies and other telecommunications service providers. Conference Plus, Inc. is a leading global provider of audio, web, video and IP conferencing services. Additional information can be obtained by visiting http://www.westell.com and http://www.conferenceplus.com.

About Arkadin

Arkadin is a global Collaboration Service Provider, offering audio, web, and video conferencing, online events, and unified communication solutions. Arkadin enables organizations to communicate and collaborate using customizable, cost-efficient, user-friendly solutions. Founded in 2001, Arkadin has 47 operating centers in 28 countries throughout Asia, Europe, Middle East, Africa and North America, offering a full suite of remote collaboration solutions to more than 14,000 clients. To find out more about Arkadin please visit www.arkadin.com.

“Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995:

Certain statements contained herein that are not historical facts or that contain the words “believe”, “expect”, “intend”, “anticipate”, “estimate”, “may”, “will”, “plan”, “should”, or derivatives thereof and other words of similar meaning are forward-looking statements that involve risks and uncertainties. Actual results may differ materially from those expressed in or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, product demand and market acceptance risks, need for financing and capital, economic weakness in the United States economy and telecommunications market, the impact of competitive products or technologies, competitive pricing pressures, customer product selection decisions, product cost increases, component supply shortages, new product development, excess and obsolete inventory, commercialization and technological delays or difficulties (including delays or difficulties in developing, producing, testing and selling new products and technologies), the effect of Westell’s accounting policies, the need for additional capital, the effect of international economic conditions and trade, legal, social and economic risks (such as import, licensing and trade restrictions), retention of key personnel and other risks more fully described in the Company’s SEC filings, including the Company’s Form 10-K for the fiscal year ended March 31, 2011 under the section entitled Risk Factors. The Company undertakes no obligation to publicly update these forward-looking statements to reflect current events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events, or otherwise.

Presenting from the Company will be James D. White, chairman, president and CEO. The presentation will begin at 11:05 a.m. Eastern Time.

Investors and interested parties may listen to the live webcast of this presentation by visiting the Company’s website at www.jambajuice.com under the Investor Relations section at the appropriate time.

About Jamba, Inc.

Jamba, Inc. is a holding company which owns and franchises, on a global basis, Jamba Juice stores through its wholly-owned subsidiary, Jamba Juice Company. Jamba Juice Company is a leading restaurant retailer of better-for-you beverage and food offerings, which include great tasting fruit smoothies, fresh juices and teas, hot oatmeal made with organic steel cut oats, fruit and veggie smoothies, Whirl’ns™ Frozen Yogurt, breakfast wraps, salads, sandwiches, California Flatbreads™, and a variety of baked goods and snacks. As of October 4, 2011, there were 752 locations in the United States consisting of 310 Company-owned and operated stores and 442 franchise-operated stores. In addition, at October 4, 2011 there were 10 international stores.

“Fortress is very well-positioned today, and across our company, we remain single-mindedly focused on managing our investment funds and capitalizing on opportunities to create value for our investors. We look forward to Dan’s return in the hope that matters are resolved favorably and expeditiously.”

“I have requested a leave of absence from my position as chief executive officer to ensure that any time or attention I need to focus on matters outside of Fortress will not affect the business or operations of the company,” said Mr. Mudd.

“We are grateful to Dan for his service and leadership over the past two and a half years and support his decision to take a leave of absence at this point in time,” said Mr. Nardone. “Fortress is very well-positioned today, and across our company, we remain single-mindedly focused on managing our investment funds and capitalizing on opportunities to create value for our investors. We look forward to Dan’s return in the hope that matters are resolved favorably and expeditiously.”

Mr. Nardone is a co-founder and principal of Fortress and has been a member of the Board of Directors of Fortress Investment Group LLC since November 2006. He has been a member of the Management Committee of Fortress since 1998. Prior to co-founding Fortress in 1998, Mr. Nardone was a managing director of UBS from May 1997 to May 1998. Before joining UBS, Mr. Nardone was a principal of BlackRock Financial Management, Inc. Prior to joining BlackRock, Mr. Nardone was a partner and a member of the executive committee at the law firm of Thacher Proffitt & Wood.

About Fortress

Fortress is a leading global investment manager with approximately $43.6 billion in assets under management as of September 30, 2011. Fortress offers alternative and traditional investment products and was founded in 1998. For more information regarding Fortress Investment Group LLC, please visit www.fortress.com.

“Jones & Bartlett immediately solved its data management and protection challenges by embracing virtualization technology to radically simplify and transform its IT operations”

Jones & Bartlett turned to Actifio’s PAS platform to radically reduce costs and streamline IT operations while improving the overall user experience. The seven-person IT team at Jones & Bartlett wanted a single data protection and disaster recovery solution that was compatible with its VMware-driven virtualized server environment. With the Actifio PAS platform, the simplicity of application-centric data management with Service Level Agreements (SLAs) for protection and recovery reduced the number of operational steps while the platform’s effectiveness freed up senior IT team members to focus on more strategic initiatives.

The dramatic reduction in costs comes from three areas: elimination of backup software, shrinking the storage footprint and reducing the tape media consumption. Jones & Bartlett joins a fast growing group of organizations replacing their existing backup software with Actifio’s PAS solution, eliminating $12,000 per month in software license and maintenance costs. This represented a tremendous breakthrough in efficiency according to Jones & Bartlett Vice President of Information Technology James Walsh.

“We are absolutely delighted with Actifio’s PAS platform – it unites all the enabling technologies in one simple, powerful solution simultaneously,” said Walsh. “Not only did it dramatically reduce costs and transform our IT operations, the PAS platform also fully supports VMware instant Backup and Restore while reducing our reliance on tape and deploying disaster recovery on an SMB budget without the costly networking expense of WAN accelerators, expensive network pipes and software. For busy, resource-constrained, time-pressed IT teams, Actifio’s PAS platform is truly the most effective data management platform available today.”

Walsh and his team evaluated a variety of storage tools – including deduplication backup-to-disk devices, host-level deduplication backup software, replication software/appliances, VMware snapshots and multiple point tools – before selecting Actifio’s PAS platform. According to Walsh, only Actifio’s PAS platform could deliver all of Jones & Bartlett’s data management and protection requirements within a single, cost-efficient solution. After deploying PAS, Walsh and his team realized immediate benefits, including shrinking the storage footprint by more than 95 percent and reducing tape media costs by 65 percent.

“Jones & Bartlett immediately solved its data management and protection challenges by embracing virtualization technology to radically simplify and transform its IT operations,” said Ash Ashutosh, founder and CEO of Actifio. “More and more customers are eager to break free from outdated, complex backup solutions using backup software that causes more problems than it solves. Jones & Bartlett joins a rapidly growing base of users who are getting rid of backup software to enhance their backup and data recovery capabilities while achieving dramatic cost savings and operational efficiencies.”

Additional Resources

For more background on the benefits Jones & Bartlett has achieved, visit http://www.actifio.com/resources/videos/ to view a brief video.

About Actifio

Actifio™, the Protection and Availability Storage (PAS) platform company, pioneered the industry’s first storage system optimized for managing copies of production data, eliminating redundant silos of IT infrastructure and data management applications. By introducing virtualization into data management, Actifio delivers an application-centric, SLA-driven solution that decouples the management of data from storage, network and server infrastructure and reduces costs by 10X. Actifio has helped liberate IT organizations and services providers of all sizes from vendor lock-in and the management challenges associated with exploding data growth. Actifio is headquartered in Waltham, Mass. with offices around the world. For more information, please visit: http://www.actifio.com.

Copyright © 2011 Actifio, Inc. All Rights Reserved. All other brand names, product names, or trademarks belong to their respective holders.

“The new credit facility will be used for working capital, acquisitions, capital expenditures, investments and general corporate purposes and replaces an existing £102 million credit facility with the Royal Bank of Scotland that was scheduled to mature in November 2013”

“The new credit facility in the U.K. provides sufficient capital to support continued growth and flexibility in the U.K. and demonstrates the confidence of our financial partners in the business model,” said David K. Jones, Executive Vice President and Chief Financial Officer for Penske Automotive Group. “The new credit facility will be used for working capital, acquisitions, capital expenditures, investments and general corporate purposes and replaces an existing £102 million credit facility with the Royal Bank of Scotland that was scheduled to mature in November 2013,” added Jones.

About Penske Automotive

Penske Automotive Group, Inc., headquartered in Bloomfield Hills, Michigan, operates 321 retail automotive franchises, representing 42 different brands and 28 collision repair centers. Penske Automotive, which sells new and previously owned vehicles, finance and insurance products and replacement parts, and offers maintenance and repair services on all brands it represents, has 166 franchises in 17 states and Puerto Rico and 155 franchises located outside the United States, primarily in the United Kingdom. Penske Automotive is a member of the Fortune 500 and Russell 2000 and has approximately 15,000 employees.

Statements in this press release may involve forward-looking statements, including forward-looking statements regarding PAG. Actual results may vary materially because of risks and uncertainties as well as external factors such as consumer credit conditions, macro-economic factors; interest rate fluctuations; changes in consumer spending; and other factors over which management has no control. These forward-looking statements should be evaluated together with additional information about PAG’s business, markets, conditions and other uncertainties, which could affect PAG’s future performance, which are contained in the Company’s Form 10-K for the year ended December 31, 2010, and its other filings with the Securities and Exchange Commission and which are incorporated into this press release by reference. This press release speaks only as of its date, and Penske Automotive Group, Inc. disclaims any duty to update the information herein.

Find a vehicle: http://www.penskecars.com

Engage Penske Automotive: http://www.penskesocial.com

Like Penske Automotive on Facebook: https://facebook.com/PenskeCars

Follow Penske Automotive on Twitter: https://twitter.com/#!/Penskecarscorp

Visit Penske Automotive on YouTube: http://www.youtube.com/penskecars

„Der neue Kreditrahmen wird für Betriebsmittel, Akquisitionen, Kapitalaufwendungen, Investitionen und allgemeine betriebliche Zwecke verwendet und ersetzt einen vorhandenen Kreditrahmen über 102 Millionen Britischer Pfund bei der Royal Bank of Scotland, der im November 2013 ausgelaufen wäre“

„Der neue Kreditrahmen liefert genügend Kapital für anhaltendes Wachstum und Flexibilität in Großbritannien und spiegelt das Vertrauen unserer Finanzpartner in das Geschäftsmodell wider“, sagte David K. Jones, Executive Vice President und Chief Financial Officer der Penske Automotive Group. „Der neue Kreditrahmen wird für Betriebsmittel, Akquisitionen, Kapitalaufwendungen, Investitionen und allgemeine betriebliche Zwecke verwendet und ersetzt einen vorhandenen Kreditrahmen über 102 Millionen Britischer Pfund bei der Royal Bank of Scotland, der im November 2013 ausgelaufen wäre“, fügte Jones hinzu.

Über Penske Automotive

Penske Automotive Group, Inc. hat seinen Hauptsitz in Bloomfield Hills, Michigan, USA, und betreibt 321 Fahrzeugeinzelhandels-Franchise-Betriebe, die 42 unterschiedliche Marken abdecken, sowie 28 Unfallwerkstätten. Penske Automotive vertreibt Neu- und Gebrauchtwagen, Finanzierungs- und Versicherungsprodukte sowie Ersatzteile und bietet Wartungs- und Reparaturdienstleistungen für alle durch das Unternehmen vertriebenen Marken an. Penske Automotive verfügt über 166 Filialen in 17 US-Bundesstaaten und in Puerto Rico sowie über 155 Filialen außerhalb der USA, hauptsächlich in Großbritannien. Penske Automotive ist Mitglied der Indizes Fortune 500 und Russell 2000 und hat etwa 15.000 Mitarbeiter.

Die Erklärungen in dieser Pressemitteilung können zukunftsgerichtete Aussagen enthalten, darunter zukunftsgerichtete Aussagen bezüglich PAG. Die tatsächlichen Ergebnisse können aufgrund von Risiken und Ungewissheiten sowie externen Faktoren wesentlich abweichen. Hierzu gehören die Verbraucherkreditkonditionen, makroökonomische Faktoren, Zinssatzschwankungen, Änderungen bei den Verbraucherausgaben und andere Faktoren, auf die die Unternehmensführung keinen Einfluss hat. Diese zukunftsgerichteten Aussagen sollten zusammen mit zusätzlichen Informationen über die Geschäfte, Märkte, Konditionen von PAG und andere Ungewissheiten überprüft werden, die die zukünftigen Leistungen von PAG beeinflussen könnten. Diese sind im Formblatt 10-K für das am 31. Dezember 2010 endende Kalenderjahr und in den anderen Einreichungen des Unternehmens bei der US-Börsenaufsichtsbehörde SEC enthalten und gehören als Bezugsurkunden zu dieser Pressemitteilung. Diese Pressemitteilung bezieht sich lediglich auf den heutigen Stand, und die Penske Automotive Group, Inc., distanziert sich von allen Verpflichtungen, die darin enthaltenen Informationen zu aktualisieren.

Finden Sie ein Fahrzeug: http://www.penskecars.com

Treten Sie mit Penske Automotive in Kontakt: http://www.penskesocial.com

Zeigen Sie auf Facebook, dass Ihnen Penske Automotive gefällt: https://facebook.com/PenskeCars

Folgen Sie Penske Automotive auf Twitter: https://twitter.com/#!/Penskecarscorp

Besuchen Sie Penske Automotive auf YouTube: http://www.youtube.com/penskecars

Die Ausgangssprache, in der der Originaltext veröffentlicht wird, ist die offizielle und autorisierte Version. Übersetzungen werden zur besseren Verständigung mitgeliefert. Nur die Sprachversion, die im Original veröffentlicht wurde, ist rechtsgültig. Gleichen Sie deshalb Übersetzungen mit der originalen Sprachversion der Veröffentlichung ab.

“With the rate of technology change continuing to accelerate, organizations more than ever require well-designed policies and procedures to ensure that employees use technology appropriately”

“With the rate of technology change continuing to accelerate, organizations more than ever require well-designed policies and procedures to ensure that employees use technology appropriately,” stated Wallace. “Since each organization is different, our book helps IT leaders develop policies that meet their unique situation.”

Wallace has more than 25 years of experience in the information systems field. He graduated magna cum laude from Wright State University with a Bachelor of Science degree in Management Science, and later graduated from the Executive MBA program at the Fisher College of Business at The Ohio State University. Recently he was elected to the position of secretary/treasurer for the International Association of Microsoft Channel Partners (IAMCP) for the Tennessee chapter.

Wallace has worked as an application developer, a systems analyst, and a technical and business consultant and has assisted the state of Ohio in developing statewide IT policies. He’s active in the local technical community, and is past president of the Columbus International Association of Microsoft Channel Partners (IAMCP). He has taught at The Ohio State University and at DeVry University’s Keller Graduate School of Management, and has published several articles and books on business and technology topics.

IT Governance: Policies and Procedures provides fingertip access to the information needed on policy and planning, documentation, systems analysis and design, and provides readers with models or templates to create similar documents for their own organizations.

Highlights of the 2012 Edition include:

• New chapters covering risk management, Agile project management, and building the right employee skills
• Sixty IT policies that can be used right away to better govern IT processes
• New information on how to safely allow remote access to an organization’s network
• Information on how to protect networks from harm caused by the use of personal devices
• Best practices on how to simplify processes for greater manpower efficiency and fewer errors
• An updated glossary with the latest IT and business terms
• Information on how quality assurance drives the predictability of IT service delivery
• Tips for using quality control to improve IT process effectiveness

About InfoSystems

Since 1994, InfoSystems has been, and continues to be, the approachable provider of reliable technology solutions for enterprise and small-to-medium sized businesses. InfoSystems is one of the fastest-growing IT, communications and software solutions providers in the Chattanooga, Knoxville and Nashville, Tennessee areas. A unique business-first approach layered with IT expertise has led InfoSystems to receive numerous industry and community awards. InfoSystems offers four areas of expertise: Technology Solutions, including storage and information solutions, infrastructure optimization, and disaster recovery; Communications Services, for scalable, efficiency-centric platform solutions of unified communications that optimize productivity and cut costs; Software Services, including collaboration, custom software and applications development, plus integration, legacy and migration solutions; and iAssurance Managed Services, a predictable and economical investment in 24/7 reliability and stability.

The Global Natural Resources Investors Guide is a database specifically designed for companies in the natural resources industries. This includes mining companies, oil and gas companies that are engaged in the mining activities. This database covers institutions and strategic investors that are active in natural resources opportunities. These include institutions that invest in mining, oil and gas sectors. The 2nd file contains strategic investors such as steel companies, and mining companies that are actively investing in new projects or investing in other mining companies.

Highlights of this report:

1) Inclusion of investment institutions from Americas, Europe and Asia Pacific regions

2) Inclusion of different strategic investors for natural resources, oil and gas sectors

3) Mining, steel companies, mining investment institutions

4) Available in Excel format.

Reasons why buyers have purchased this database:

1) Junior resources companies looking for investment capital

2) Resources companies looking for investors or strategic investors for their expansions

3) Investor relations companies and financial professionals looking for information relating to mining investments

4) Mining companies seeking strategic investors like steel companies

What Kind of Industries do these firms invest?

• Base Metals
• Iron Ore
• Copper
• Nickel
• Coal
• Oil
• Gas
• Uranium
• Diamond
• Gold
• Silver
• Other Precious Metals
• Mining Infrastructure Financing

For more information visit http://www.researchandmarkets.com/research/75494b/global_natural_res

“Consumer Trends in the Personal Hygiene Market in Germany , 2011”

This report provides the results for the Personal Hygiene market in Germany from Canadean's unique, highly detailed and proprietary study of consumers' Consumer Packaged Goods (CPG) consumption habits, and forms part of an overall series covering all CPG product markets.

Its coverage includes, but is not limited to, consumption behaviours, the extent to which consumer trends influence their consumption and the value of the market these trends influence, brand and private label choices as well as retailer choices. Much of this information can also be analyzed by specific consumer group, providing hard and fast data on consumers and markets at the product category level.

Marketers in the Personal Hygiene market in Germany face a major challenge. Understanding market size and segmentation is valuable, but the keys to effective targeting is knowing just how valuable specific consumer groups are, and being able to quantify the impact of consumer trends.

This report provides integrated data on consumer trends, consumer groups and market data which show exactly the size of consumer groups, how much of the Personal Hygiene market in Germany they account for and which consumer trends drive their behaviour, and as such allows marketers to develop strong growth strategies.

Consumers' uptake of products and the influence of consumer trends are fundamental causes of change in markets - and as such marketers need to know what these trends are and be able to quantify their influence in the market. This report provides highly detailed insight into exactly who the consumer is and how the latest consumer trends are changing the market by examining over 20 consumer trends and the share of sales across over 30 consumer groups.

Key Topics Covered:

1 Introduction

2 Consumer Segmentation, Group Value and Trend Influence

3 Consumption Analysis

4 Brand vs. Private Label Choices

5 The Share of Consumers influenced by Trends

6 Consumption Impact: Market Valuation

7 Retailer Choice, Switching and Category Share

8 Appendix

For more information visit http://www.researchandmarkets.com/research/52bd0f/consumer_trends_in

“We hope everyone will express their inner Santa Claus this season by taking part in our ‘Arctic Home’ initiative to help polar bears and by supporting Toys for Tots in their local communities.”

Coca-Cola is celebrating its fifth year of partnership with Toys for Tots by donating more than a quarter million dollars of Arctic-themed gifts to local Toys for Tots chapters in seven U.S. cities, including: Los Angeles, Dallas, Seattle, Charlotte, Chicago, New York and Cincinnati. The toys and gifts for kids of all ages include plush polar bears and polar bear hats, plus white MP3 players, skateboards, watches and Velcro wallets. By sharing Arctic-themed gifts, Coca-Cola is helping bring holiday joy to those who need it most, while reminding people to take part in the “Arctic Home” program.

“This season, we’re giving back to our local communities with Toys for Tots, while also raising awareness about our ‘Arctic Home’ initiative to support polar bears,” said Stuart Kronauge, Senior Vice President, Coca-Cola Trademark Marketing, Coca-Cola North America. “We hope everyone will express their inner Santa Claus this season by taking part in our ‘Arctic Home’ initiative to help polar bears and by supporting Toys for Tots in their local communities.”

“Arctic Home” is an initiative between Coca-Cola and World Wildlife Fund (WWF) to raise awareness and generate funds to help protect the polar bear’s Arctic habitat. To support polar bears, people can look for limited-edition “Arctic Home” cans and caps on Coke products and donate $1 by texting the package code to 357357. All donations go to WWF’s efforts to protect the polar bear’s Arctic home. Donations can also be made online at ArcticHome.com. From the website, people can help spread the word to their friends and families by sharing content on Facebook and Twitter using the hashtag #ArcticHome. Coca-Cola will match all donations made with a package code by March 15, 2012, up to $1 million.

“We are grateful for the very generous donation from Coca-Cola to local communities across the nation, and we appreciate the continued partnership,” said Marine Major Bill Grein, Vice President of the Marine Toys for Tots Foundation. “These gifts will help children and teens in need enjoy the magic of the Christmas holiday season.”

The U.S. Marine Corps Reserve Toys for Tots Program is dependent on charitable giving during this time of year. Donations are always in high demand around the holidays, and the need for toys has skyrocketed in the past year.

Coca-Cola has a long tradition of giving back at the holidays and sharing season’s greetings and cheer. With holiday packaging and advertising, the Coca-Cola Holiday Caravan tour – featuring festive Coca-Cola trucks decorated with 25,000 red and white lights – and the beloved Coca-Cola Santa, Coca-Cola is part of the celebrations that families and friends enjoy during the holidays.

About The Coca-Cola Company

The Coca-Cola Company (NYSE: KO) is the world's largest beverage company, refreshing consumers with more than 500 sparkling and still brands. Led by Coca-Cola, the world's most valuable brand, our Company’s portfolio features 15 billion dollar brands including Diet Coke, Fanta, Sprite, Coca-Cola Zero, vitaminwater, Powerade, Minute Maid, Simply, Georgia and Del Valle. Globally, we are the No. 1 provider of sparkling beverages, ready-to-drink coffees, and juices and juice drinks. Through the world's largest beverage distribution system, consumers in more than 200 countries enjoy our beverages at a rate of 1.7 billion servings a day. With an enduring commitment to building sustainable communities, our Company is focused on initiatives that reduce our environmental footprint, support active, healthy living, create a safe, inclusive work environment for our associates, and enhance the economic development of the communities where we operate. Together with our bottling partners, we rank among the world’s top 10 private employers with more than 700,000 system employees. For more information, please visit www.thecoca-colacompany.com or follow us on Twitter at twitter.com/CocaColaCo.

About “Arctic Home”

Inspired by the threat facing the polar bear and its habitat, Coca-Cola and World Wildlife Fund (WWF) are joining forces to help protect the polar bear’s home. Together we are raising awareness and funds for the creation of an Arctic refuge for the polar bear. As part of the “Arctic Home” effort, Coca-Cola is committing $2 million. From the www.ArcticHome.com site, people can help us spread the word to their friends and families by sharing content on Facebook and Twitter using the hashtag #ArcticHome.

About Toys for Tots

Toys for Tots, a 65 year national charitable program run by the U.S. Marine Corps Reserve, provides happiness and hope to economically disadvantaged children during each Christmas holiday season. The toys, books and other gifts collected and distributed by the Marines offer these children recognition, confidence and a positive memory for a lifetime. It is such experiences that help children become responsible citizens and caring members of their community. Last year the Marine Corps fulfilled the holiday hopes and dreams of 7.2 million less fortunate children in over 700 communities nationwide. For more information, visit www.toysfortots.org.

Nel 2011, sono state pubblicate quattro nuove Linee guida con raccomandazioni sui test di reattività piastrinica per i pazienti in terapia antipiastrine: ACCF/AHA per pazienti UA/NSTEMI¹, ACCF/AHA/SCAI per pazienti PCI², ESC per pazienti NSTE-ACS³ e STS/SCA per pazienti sottoposti a intervento chirurgico⁴.

Il testo originale del presente annuncio, redatto nella lingua di partenza, è la versione ufficiale che fa fede. Le traduzioni sono offerte unicamente per comodità del lettore e devono rinviare al testo in lingua originale, che è l'unico giuridicamente valido.

“The combination of the management team’s experience and focus makes the company attractive. We are excited about the prospects for growth in this sector and are pleased to be on this path with NexSteppe.”

The biobased industries that NexSteppe’s products serve are experiencing rapid growth driven by volatile fossil fuel prices, a desire for energy security, and growing concerns about the environmental impacts of fossil fuel use. Sugars and biomass from NexSteppe’s tailored crops can be processed by biorefineries, sugar to ethanol mills, and coal or biomass-fired power plants into a myriad of products ranging from fuels to power to plastics to cosmetics. While each application has its unique feedstock requirements, they all require scalable, reliable and sustainable feedstocks that won’t negatively impact the environment or the world’s food supply. Dedicated crops, optimized for these applications, hold the promise for bioenergy and biobased products to become mainstream, sustainable solutions. NexSteppe is focused on developing these crops, as well as the supply chains that will enable their widespread adoption.

The company will use the proceeds from the round to scale up its sweet sorghum, high biomass sorghum and switchgrass breeding programs, and to advance its first products toward commercialization. According to NexSteppe founder and CEO, Anna Rath, “NexSteppe has assembled a world class team that brings to this industry a new level of operational experience and commercial orientation. We look forward to working with our customers to solve their feedstock problems and meet their feedstock needs.”

The new round of funding was led by Braemar Energy Ventures, a leading energy venture capital firm with a strong portfolio of investments in alternative energy and energy efficiency. In connection with Braemar’s investment in NexSteppe, Dennis Costello, Partner at Braemar Energy Ventures, has joined the company’s Board of Directors.

”We have long believed that feedstock is a critical component in the value chains for biofuels and biobased products. We view NexSteppe’s strategy of focusing on dedicated crops produced from seed, some of which can offer drop-in solutions in existing value chains, as a winning one,” said Dennis Costello. “The combination of the management team’s experience and focus makes the company attractive. We are excited about the prospects for growth in this sector and are pleased to be on this path with NexSteppe.”

Braemar was joined by returning investors CYM Ventures and Zygote Ventures among others. CYM Ventures is the investment company of a third generation, family-owned and operated agricultural business in Asia. CYM is committed to the belief that agriculture will play a vital role in the coming years, to provide for the needs of an ever growing world. Zygote Ventures is a privately held seed/angel venture capital fund that invests very early in innovative technology enterprises. Zygote is run by principal Jerry Fiddler, Chairman of Solazyme and founder of Wind River.

About NexSteppe

NexSteppe is dedicated to pioneering the next generation of scalable, reliable, cost-effective and sustainable feedstock solutions for the biofuels, biopower and biobased products industries. Through the development and commercialization of tailored crops and fully-integrated feedstock solutions, NexSteppe is laying a foundation for a more secure and sustainable future for our economy, our environment, and our energy supply. For more information, please visit www.nexsteppe.com.

About Braemar Energy Ventures

Braemar Energy Ventures is a venture capital fund making early to mid-stage investments in the energy technology sector. The firm's principals have invested in more than 50 companies in the sector and have significant technical, operational and financial experience in energy and energy-related industries. Through offices in New York and Boston, the firm targets a wide range of energy technologies that impact stationary power, transportation and portable energy applications. Additional information is available at www.braemarenergy.com.

The NexSteppe logo and NexSteppe™ are trademarks of NexSteppe.

“The option to use USCN’s hybridomas for the manufacture of the antibody components of PanC-DxTM will allow OncoCyte to keep the development of its lead human pan-cancer diagnostic product on the fast track”

In addition to this option agreement, BioTime and USCN signed a distribution agreement granting BioTime and its subsidiaries the right to market over four thousand diverse ELISA and CLIA kits for detecting a wide array of other proteins for the stem cell research market. Beginning in 2012, BioTime plans to sell these research products through its subsidiary LifeMap Sciences, Inc.

Background

OncoCyte scientists have identified a pattern of proteins produced by tumors that can be detected in the blood of cancer patients, but not in the blood of healthy people. In laboratory tests, the percentage of times that the test correctly identified people as having cancer versus being cancer-free was higher than that of commonly used cancer diagnostics such as the prostate-specific antigen test for prostate cancer. The use of new cancer diagnostics is experiencing rapid growth; according to data from Business Insights, Ltd. revenues will reach US $8.14 billion by 2014, thus outpacing the growth of the general diagnostics market.

OncoCyte intends to initially develop and market PanC-Dx^TM in Europe before seeking regulatory approvals required to market the product in the United States and other countries. OncoCyte will be pursuing full medical device quality system certification, which should be achieved by the fourth quarter of 2013.

An important factor in the rapid development of antibody-based diagnostics is a scalable source of the antibodies that specifically recognize a target protein. USCN Life Sciences offers thousands of diverse antibody-based assay kits for enzyme-linked immunosorbent assay (ELISA) and chemiluminescent immuno-assay (CLIA). These kits utilize antibodies that recognize a wide array of proteins and are useful in the measurement of the levels of these proteins for research purposes. These antibodies are produced from cell lines called hybridomas. A hybridoma cell line is an expandable culture of cells engineered to secrete a distinct antibody known as a monoclonal antibody that is directed to a specific protein. The specific combination of antibodies in PanC-Dx^TM useful in diagnosing tumors in patients is proprietary technology developed by OncoCyte. As a result of the agreement with USCN, OncoCyte will have the choice of creating its own antibody-producing cell lines to manufacture the components of PanC-Dx^TM, or of saving time and development costs by using existing USCN hybridomas under a royalty-bearing license.

“The option to use USCN’s hybridomas for the manufacture of the antibody components of PanC-Dx^TM will allow OncoCyte to keep the development of its lead human pan-cancer diagnostic product on the fast track,” said Michael D. West, Ph.D., CEO of BioTime. “We are also impressed with the quality of the antibody-based products manufactured by USCN Life Sciences, and look forward to collaborating with USCN to distribute over 4,000 diverse ELISA and CLIA kits to the stem cell research community through the LifeMap database currently under development by LifeMap Sciences Ltd. of Tel Aviv, Israel.”

About BioTime, Inc.

BioTime, headquartered in Alameda, California, is a biotechnology company focused on regenerative medicine and blood plasma volume expanders. Its broad platform of stem cell technologies is developed through subsidiaries focused on specific fields of applications. BioTime develops and markets research products in the field of stem cells and regenerative medicine, including a wide array of proprietary ACTCellerate™ cell lines, culture media, and differentiation kits. BioTime's wholly owned subsidiary ES Cell International Pte. Ltd. has produced clinical-grade human embryonic stem cell lines that were derived following principles of Good Manufacturing Practice and currently offers them for use in research. BioTime's therapeutic product development strategy is pursued through subsidiaries that focus on specific organ systems and related diseases for which there is a high unmet medical need. BioTime's majority owned subsidiary Cell Cure Neurosciences, Ltd. is developing therapeutic products derived from stem cells for the treatment of retinal and neural degenerative diseases. Cell Cure's minority shareholder Teva Pharmaceutical Industries has an option to clinically develop and commercialize Cell Cure's OpRegen™ retinal cell product for use in the treatment of age-related macular degeneration. BioTime's subsidiary OrthoCyte Corporation is developing therapeutic applications of stem cells to treat orthopedic diseases and injuries. Another subsidiary, OncoCyte Corporation, focuses on the diagnostic and therapeutic applications of stem cell technology in cancer, including using vascular progenitor cells engineered to destroy malignant tumors. ReCyte Therapeutics, Inc. is developing applications of BioTime's proprietary induced pluripotent stem cell technology to reverse the developmental aging of human cells to treat cardiovascular and blood cell diseases. BioTime's newest subsidiary, LifeMap Sciences, Inc., is developing an online database of the complex cell lineages arising from stem cells to guide basic research and to market BioTime's research products. In addition to its stem cell products, BioTime develops blood plasma volume expanders, blood replacement solutions for hypothermic (low-temperature) surgery, and technology for use in surgery, emergency trauma treatment and other applications. BioTime's lead product, Hextend®, is a blood plasma volume expander manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ CheilJedang Corp. under exclusive licensing agreements. Additional information about BioTime, ReCyte Therapeutics, Cell Cure, OrthoCyte, OncoCyte, BioTime Asia, LifeMap Sciences, and ESI can be found on the web at www.biotimeinc.com.

About USCN Life Science, Inc.

USCN Life Science Inc. is a biotechnology company based in Wuhan, China, concentrating on producing detection reagents and related biological reagents used primarily for academic research. USCN applies innovative techniques to efficiently extract and isolate natural proteins from both animal and plant sources. USCN also obtains recombinant proteins by gene construction, expression and protein purification. Researchers in USCN’s Antibody Center are able to modify small molecules to improve immunogenicity. They have accumulated rich experience and mastered the methods of immunizing, collecting, fusing, selecting, isolating, and purifying polyclonal antibodies, as well as preparing, identifying, and storing those antibodies. USCN’s automated production technology ensures the stability of product quality and reduces intra-assay coefficient variations. Through its Technology & Quality Department, USCN enforces technical parameters and quality standards, and provides after-sale service and technical consultation for the company’s customers.

Forward-Looking Statements

Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for BioTime and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of BioTime and its subsidiaries, particularly those mentioned in the cautionary statements found in BioTime's Securities and Exchange Commission filings. BioTime disclaims any intent or obligation to update these forward-looking statements.

To receive ongoing BioTime corporate communications, please click on the following link to join our email alert list: http://www.b2i.us/irpass.asp?BzID=1152&to=ea&s=0

“Circadian Rhythm Sleep Disorders Global Clinical Trials Review, H2, 2011”

GlobalData's clinical trial report, Circadian Rhythm Global Clinical Trials Review, H2, 2011" provides data on the Circadian Rhythm clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Circadian Rhythm. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Circadian Rhythm. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

• Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
• Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
• Listings of discontinued trials (suspended, withdrawn and terminated)

Key Topics Covered:

• Introduction
• Circadian Rhythm Sleep Disorders
• Report Guidance
• Clinical Trials by Region
• Clinical Trials by Country
• Top Countries Contributing to Clinical Trials in Asia-Pacific
• Top Five Countries Contributing to Clinical Trials in Europe
• Top Countries Contributing to Clinical Trials in North America
• Clinical Trials by G7 Nations
• Clinical Trials in G7 Nations by Trial Status
• Clinical Trials by Phase
• In Progress Trials by Phase
• Clinical Trials by Trial Status
• Unaccomplished Trials of Circadian Rhythm Sleep Disorders
• Subjects Recruited Over a Period of Time
• Prominent Sponsors
• Top Companies Participating in Circadian Rhythm Sleep Disorders Therapeutics Clinical Trials
• Prominent Drug Comparison
• Clinical Trial Profiles
• Clinical Trial Overview of Top Companies
• Five Key Clinical Profiles
• Appendix
• Abbreviations
• Definitions
• Research Methodology
• Secondary Research

For more information visit http://www.researchandmarkets.com/research/a109d8/circadian_rhythm_s

“Lymphedema Global Clinical Trials Review, H2, 2011”

GlobalData's clinical trial report, Lymphedema Global Clinical Trials Review, H2, 2011" provides data on the Lymphedema clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Lymphedema. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Lymphedema. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

• Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
• Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
• Listings of discontinued trials (suspended, withdrawn and terminated)

Key Topics Covered:

• Introduction
• Lymphedema
• Report Guidance
• Clinical Trials by Region
• Clinical Trials by Country
• Top Countries Contributing to Clinical Trials in Asia-Pacific
• Top Countries Contributing to Clinical Trials in Europe
• Top Countries Contributing to Clinical Trials in North America
• Top Countries Contributing to Clinical Trials in Central and South America
• Clinical Trials by G7 Nations
• Clinical Trials in G7 Nations by Trial Status
• Clinical Trials by E7 Nations
• Clinical Trials in E7 Nations by Trial Status
• Clinical Trials by Phase
• In Progress Trials by Phase
• Clinical Trials by Trial Status
• Unaccomplished Trials of Lymphedema
• Subjects Recruited Over a Period of Time
• Prominent Sponsors
• Top Companies Participating in Lymphedema Therapeutics Clinical Trials
• Clinical Trial Profiles
• Clinical Trial Overview of Top Companies
• Five Key Clinical Profiles
• Appendix
• Abbreviations
• Definitions
• Research Methodology
• Secondary Research

For more information visit http://www.researchandmarkets.com/research/78850f/lymphedema_global